Fidelity Investments’s Inhibikase Therapeutics IKT Stock Holding History

Fidelity Investments’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$211K	Buy	103,727 +31,764	+44%	+$56.9K	﹤0.01%	3640
2026 Q1	$121K	Buy	71,963 +14,589	+25%	+$25.9K	﹤0.01%	3722
2025 Q4	$118K	Sell	57,374 -48,396	-46%	-$77K	﹤0.01%	3675
2025 Q3	$171K	Sell	105,770 -38,469	-27%	-$66.6K	﹤0.01%	3423
2025 Q2	$281K	Buy	+144,239	New	+$282K	﹤0.01%	3185
2022 Q4	–	Sell	-72,217	Closed	-$394K	–	5473
2022 Q3	$394K	Hold	72,217	–	–	﹤0.01%	2853
2022 Q2	$322K	Hold	72,217	–	–	﹤0.01%	2985
2022 Q1	$641K	Hold	72,217	–	–	﹤0.01%	2910
2021 Q4	$637K	Hold	72,217	–	–	﹤0.01%	2746
2021 Q3	$823K	Hold	72,217	–	–	﹤0.01%	2722
2021 Q2	$1.21M	Buy	72,217 +55,550	+333%	+$1.63M	﹤0.01%	2630
2021 Q1	$601K	Hold	16,667	–	–	﹤0.01%	2662
2020 Q4	$690K	Buy	+16,667	New	+$845K	﹤0.01%	2596

Other funds holding IKT

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments's IKT Position: Q2 2026 in Review

Fidelity Investments increased its Inhibikase Therapeutics (IKT) stake by 44% in Q2 2026, buying an estimated $56.9K and bringing the position to 103,727 shares worth $211K. The position accounts for ﹤0.01% of the portfolio, ranked #3640.

Fidelity Investments first reported a position in IKT in Q4 2020 and has held it in 13 quarters since. The position peaked at $1.21M in Q2 2021. 106 funds tracked by Wall St. Rank hold IKT as of Q2 2026.

Fidelity Investments held 103,727 shares of Inhibikase Therapeutics worth $211K as of Q2 2026.
Fidelity Investments bought 31,764 Inhibikase Therapeutics shares in Q2 2026, an estimated $56.9K.
Inhibikase Therapeutics made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #3640 holding.
Fidelity Investments first reported a position in Inhibikase Therapeutics in Q4 2020 and has held it in 13 quarters since.
Fidelity Investments's Inhibikase Therapeutics position peaked at $1.21M in Q2 2021.
106 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.